Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Schering Settles Off-Label Promotion, Fraud Allegations For $435 Mil.

This article was originally published in The Pink Sheet Daily

Executive Summary

Settlement with Boston U.S. Attorney’s office includes amendment to Schering-Plough’s existing OIG corporate integrity agreement.

You may also be interested in...



Cephalon Must Report Payments To Physicians In Settlement Of Off-Label Charges

Cephalon is to become the third pharmaceutical company to disclose its payments to physicians. While Lilly and Merck recently volunteered to do so, Cephalon's disclosure is mandated under a settlement agreement with the U.S. Department of Justice to resolve charges that it promoted off-label use of three drugs

Cephalon Must Report Payments To Physicians In Settlement Of Off-Label Charges

Cephalon is to become the third pharmaceutical company to disclose its payments to physicians. While Lilly and Merck recently volunteered to do so, Cephalon's disclosure is mandated under a settlement agreement with the U.S. Department of Justice to resolve charges that it promoted off-label use of three drugs

Cephalon Settles Federal Investigation Of Marketing Practices For $425 Million

Cephalon enters into a corporate integrity agreement with HHS Inspector General, which likely will be in line with its existing compliance program, firm tells “The Pink Sheet” DAILY.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS064764

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel